SERI Using TripleTOF 5600 to Validate Protein Biomarker for Dry Eye Syndrome
May 06, 2011
SERI Using TripleTOF 5600 to Validate Protein Biomarker for Dry Eye Syndrome
The institute purchased the device in December and expects that its speed will make it a good validation platform for a 400-patient trial to be done in collaboration with ocular pharmaceutical company Allergan.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Tohoku U Spinoff Targeting Pharma Industry with SRM-MS Assays for ADMET Research
August 5, 2011 / ProteoMonitor - BGI Aims to Expand Proteomics Services, Purchase 50-Plus New Mass Spectrometers
June 17, 2011 / ProteoMonitor - Hutch, Broad Teams Publish Comprehensive Methods for MS-Based Biomarker Discovery and Verification
July 29, 2011 / ProteoMonitor - ETH Team Publishes Method for High-Throughput Quantitation of Whole Proteomes
July 22, 2011 / ProteoMonitor - Strong TripleTOF 5600 Sales Drive Mid-Teens Q2 Growth at AB Sciex
July 22, 2011 / ProteoMonitor